Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
09/2003
09/04/2003US20030166592 For treatment of metabolic disorders (diabetes, obesity)
09/04/2003US20030166590 Microsomal triglyceride transfer protein
09/04/2003US20030166582 Aryl fused azapolycyclic compounds
09/04/2003US20030166581 Coadministered with caffeine, for prevention of seizures; for treatment of Parkinson's/Alzheimer's disease; dietetics; smoking cessation
09/04/2003US20030166578 Combinations od dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
09/04/2003US20030166568 Organic compounds
09/04/2003US20030166559 Comprises tumor necrosis factor antagonist activity for treatment of autoimmune conditions
09/04/2003US20030166556 Immunoregulator
09/04/2003US20030166537 Use of a gial cell line-derived growth factor (GDNF) or a functionally active derivative or part thereof and/or an agonist which substitutes the functional activity of GDNF, and/ or a nucleic acid containing at least a nucleotide
09/04/2003US20030166534 Suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes,
09/04/2003US20030166530 Conjugate heat shock protein-binding peptides
09/04/2003US20030166277 Targeted vaccine delivery systems
09/04/2003US20030166258 Saccharomyces cerevisiae yeast strain with functional expression of a glut transporter
09/04/2003US20030166239 Bone morphogenic proteins; for regulating bone homeostasis, adiposity, and calcification of atherosclerotic plaques
09/04/2003US20030166228 Anti-interferon-alpha antibodies
09/04/2003US20030166189 Peptide of given amino acid sequence; sulfotransferases; useful in labeling agents with tagged sulfur, diagnosis/treatment of cancer, hypertension, renal and neurodegenerative diseases
09/04/2003US20030166140 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide polyadenylation sequence all
09/04/2003US20030165930 Polynucleotides encoding for polymorphic isoforms of the pthrp protein, the encoded proteins and their therapeutic applications thereof
09/04/2003US20030165892 Unigene unidirectional antisense library
09/04/2003US20030165604 In fats, oils; plant extracts
09/04/2003US20030165584 Agent for regulating lipidic metabolism and method for producing said agent
09/04/2003US20030165574 Compositions and methods for treatment of body weight conditions
09/04/2003US20030165569 Composition for topical substance delivery
09/04/2003US20030165501 Protein antagonist; insulin resistance; muscle disorders
09/04/2003US20030165499 Compositions and methods for treating psoriasis
09/04/2003US20030165462 Deleted adenovirus vectors and methods of making and administering the same
09/04/2003US20030165460 Proteins which control cell differentiation; immunology response; antiinflammatory agents; wound healing agents
09/04/2003US20030165449 Lipase inhibiting composition
09/04/2003CA2479812A1 Glutaminyl based dpiv inhibitors
09/04/2003CA2477558A1 N-{5-[4-(4-methyl-piperazino-methyl)­-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
09/04/2003CA2477555A1 Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient
09/04/2003CA2477031A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, the production thereof and their use in medicaments
09/04/2003CA2477008A1 Substituted pyrimidinones and pyrimidinthiones
09/04/2003CA2477005A1 Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase
09/04/2003CA2476896A1 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
09/04/2003CA2476887A1 Gasp1:a follistatin domain containing protein
09/04/2003CA2476846A1 Method for detection of leptin receptor ligands
09/04/2003CA2476654A1 Follistatin domain containing proteins
09/04/2003CA2476630A1 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
09/04/2003CA2476518A1 Compositions and methods for the treatment of immune related diseases
09/04/2003CA2476316A1 Beta3-adrenergic receptor agonists
09/04/2003CA2476173A1 Arylsulfone derivatives
09/04/2003CA2475299A1 Thiazole derivatives as npy receptor antagonists
09/04/2003CA2473340A1 Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
09/04/2003CA2471646A1 Processes and intermediates useful in preparing .beta.3-adrenergic receptor agonists
09/03/2003EP1340979A2 Neuropeptide receptor and uses thereof
09/03/2003EP1340821A2 Method of detecting a variant of gh1 as indicator of growth hormone dysfunction
09/03/2003EP1340820A2 Method of detecting a variant of gh1 as indicator of growth hormone dysfunction
09/03/2003EP1340759A1 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
09/03/2003EP1340752A1 Process for the production of semi synthetic statins via novel intermediates
09/03/2003EP1340510A1 Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
09/03/2003EP1340509A1 Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
09/03/2003EP1340508A1 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
09/03/2003EP1340504A1 Remedies for diabetes
09/03/2003EP1340500A1 Antidiabetic agents
09/03/2003EP1339843A2 Human transporter proteins nucleic acid molecules encoding them and uses thereof
09/03/2003EP1339754A1 Multicomponent compositions containing chitosan and methods of preparing same
09/03/2003EP1339748A2 G-protein coupled receptors
09/03/2003EP1339737A2 Immunomodulatory protein derived from the yaba monkey tumor virus
09/03/2003EP1339721A2 Hydroxyesters of 7-desmethylrapamycin
09/03/2003EP1339719A1 Benzimidazole derivatives, preparation and therapeutic use thereof
09/03/2003EP1339711A1 Aminothiazoles and their use as adenosine receptor antagonists
09/03/2003EP1339709A1 Farnesyl transferase inhibiting benzoheterocyclic derivatives
09/03/2003EP1339685A2 Biphenylcarboxamides useful as lipid lowering agents
09/03/2003EP1339684A1 Mch antagonists and their use in the treatment of obesity
09/03/2003EP1339683A2 Estrogen receptor modulators
09/03/2003EP1339679A1 3-arylindole derivatives and their use as cb2 receptor agonists
09/03/2003EP1339670A1 Substituted cyclohexane derivates and the use thereof in medicaments for treating cardiovascular diseases
09/03/2003EP1339662A1 Novel estrogen receptor ligands and methods iii
09/03/2003EP1339458A2 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
09/03/2003EP1339432A1 Molecular inclusion compounds consisting of biocatalytically obtained, linear, water-insoluble polysaccharides and of fatty acids or their derivatives
09/03/2003EP1339431A1 Improved oral delivery of peptides using enzyme-cleavable membrane translocators
09/03/2003EP1339429A2 Composition containing statins and calcium for improved cardiovascular health
09/03/2003EP1339424A2 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
09/03/2003EP1339416A1 Trace elements
09/03/2003EP1339413A1 Complexes of phosphate derivatives
09/03/2003EP1339412A1 Formulation containing phosphate derivatives of electron transfer agents
09/03/2003EP1339409A1 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
09/03/2003EP1339402A2 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
09/03/2003EP1339391A1 Synthesis of small particles
09/03/2003EP1339385A1 Skin cream stimulating the surface bloodstream
09/03/2003EP1339294A1 Nutritional composition for an immune condition
09/03/2003EP1196414B1 Prodrugs of carbamate inhibitors of impdh
09/03/2003EP1140187B1 Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications
09/03/2003EP1140048B1 Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases
09/03/2003EP1093451B1 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and alkanoyl l-carnitines
09/03/2003EP1090014B1 Arylsulfonanilide phosphates
09/03/2003EP1070065B1 Azabicyclic 5ht1 receptor ligands
09/03/2003EP1032381B1 Naringin and naringenin as preventive or treating agent for hepatic diseases
09/03/2003EP0977741B1 Substituted phenyl derivatives, their preparation and use
09/03/2003EP0973792B1 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives
09/03/2003EP0910372B1 Pharmaceutical compositions containing mesembrine and related compounds
09/03/2003EP0876359B1 (-) cis-6(s)-phenyl-5(r) 4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate
09/03/2003EP0833670B1 Vaccine against rotavirus infection comprising peptides of viral enterotoxin nsp4
09/03/2003EP0763116B1 Recombinant viruses, preparation and use thereof in gene therapy
09/03/2003CN1440424A Antibody selective for tumor necrosis factor-related apoptosis-inducing ligand receptor and use thereof
09/03/2003CN1440411A Aryl and heteroaryl diazabicycloalkanes, their preparation and use
09/03/2003CN1440409A Multicyclic compounds and the use as inhibitors of PARP, VEGFR2 and MLK3 enzymes
09/03/2003CN1440408A Inhibitors of human phosphatidyl-inositol 3-kinase delta
09/03/2003CN1440406A 黑皮质素受体配体 Melanocortin receptor ligands
1 ... 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 ... 1298